Skip to main content

Market Overview

UPDATE: Bank of America Lowers PO on Hologic Due to Updated Valuation

Share:

In a report published Monday, Bank of America analyst Lennox Ketner reiterated a Neutral rating on Hologic (NASDAQ: HOLX) and lowered its price objective from $24 to $21.

In the report, Bank of America cited that its new price objective, “equtes to 10x our new CY14 EBITDA estimate of $981mm. This is a slight premium to the medtech average of 9x, given HOLX's slightly higher top-line and earnings growth outlook over the next few years.”

Hologic closed Monday at $20.65.

 

Related Articles (HOLX)

View Comments and Join the Discussion!

Posted-In: Bank of America Lennox KetnerAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
GOOGLMizuhoMaintains2,600.0
VZIOWells FargoInitiates Coverage On31.0
TWTROppenheimerMaintains85.0
SBUXOppenheimerMaintains135.0
OMWells FargoInitiates Coverage On63.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com